Fungal infections in COPD

Wouter Meersseman, MD
Department of General Internal Medicine and Intensive Care Medicine
University Hospital Gasthuisberg
Leuven, Belgium.

Torino, 28 October 2007
Scope of the problem

• *What do we know?*
  
  - *Aspergillosis well known disease in hematological and solid organ transplant patients*
  
  - *Rising incidence (immunosuppressive therapy)*
  
  - *Specific diagnostic tests available in hematological patients*

• *Where do we fail in our knowledge?*
  
  - *Prevalence in COPD patients*
  
  - *Are there specific radiological or clinical signs?*
  
  - *Colonization vs disease*
Interaction of *Aspergillus* with the host

A unique microbial-host interaction

- Acute IA
- Subacute IA
- ABPA
- Allergic sinusitis
- Tracheobronchitis
- Aspergilloma
- Chronic cavitary
- Chronic fibrosing

Frequency of aspergillosis

Immune dysfunction

Normal immune function

Immune hyperactivity
The many faces of aspergillosis

From: The invasive and saprophytic syndromes due to Aspergillus spp. W W Hope, T J Walsh, D W Denning. Medical Mycology suppl 1 2005, 43, S207-S238
Types of disease in COPD

• Aspergilloma

• Chronic pulmonary aspergillosis
  1. chronic cavitary aspergillosis
  2. chronic fibrocavitary aspergillosis
  3. chronic necrotizing aspergillosis

• Subacute pulmonary invasive aspergillosis
1. Aspergilloma

= conglomeration within a pre-existing pulmonary cavity of hyphae, mucus and cellular debris
1. Aspergilloma

Benign, asymptomatic colonization, IPA rarely develops
Occurs in 10% of patients with pre-existing cavities (bullae, TBC)
1. Aspergilloma

- Precipitins: > 95% sensitivity

- Fatal asphyxiation due to massive hemoptysis may occur

- Poor prognostic signs:
  - severity of underlying lung disease
  - increasing size and number of cavities
  - immunosuppression
  - increasing IgG titers
  - sarcoidosis
  - HIV
Case

• 45-old smoker with GOLD III COPD
• On fluticasone and atropine inhalers
• Right upper lesion in 2001
• Underwent lobectomy
• 2-cm cavity with necrotic contents, pleural and parenchymal fibrosis
• No malignancy
• Cultures for *Mycobacterium* negative
Case

• 2001-2003: Never admitted with an exacerbation
• Treated twice with short course systemic steroids
• 2003-2005: intermittent hemoptysis, mild fatigue and some weight loss, no fever
• Lab results: mild to absent inflammation
• CT scan of the thorax
Case

• 2003-2005: intermittent hemoptysis, mild fatigue, some weight loss, no fever
• Lab results: mild to absent inflammation
• CT scan of the thorax
• Bronchoscopy: no lesions, cultures yield *Aspergillus fumigatus*, galactomannan OI 5 in BAL, < 0.1 in serum
• Aspergillus precipitins 3 +
• Fine needle aspiration and transbronchial biopsy: hyphae without parenchymal reaction
Treatment ???

• Stop inhaled corticosteroids?
• Systemic antifungals? Which ones? How long?
• Intracavitary instillation of antifungals?
• Interferon-gamma?
• Surgery?
• Combination of all the above treatments?

Denning DW. Chronic cavitary and fibrosing aspergillosis. Clin Infect Dis 2003:37, S265
2. Chronic aspergillosis

- Affects middle-aged persons
- Only mildly immunosuppressed (COPD, alcoholism, diabetes)
- Indolent progressive course
- Chronic cough, hemoptysis, weight loss and fatigue
- No invasion in tissue or occasionally non-angioinvasive hyphae in tissue
- Many different radiological features (cavitary, fibrosing and necrotizing)
Chronic cavitary aspergillosis in a patient with old TBC
Chronic cavitary aspergillosis in a patient with old TBC
Chronic fibrosing aspergillosis in a COPD patient
Fibrocavitary aspergillosis postpneumonectomy for chronic aspergillosis
Guidelines for treatment of chronic aspergillosis

• They do not exist !!!!
• Stop corticosteroids
• Long term oral voriconazole probably the best option
• Weight gain and improved energy levels the best indicators of response
• Search for subtle immune defects and if present, role for IFN-γ
• Surgery has a minor role

3. Subacute invasive aspergillosis

- Underrecognized disease
- ICU disease
- COPD patients with exacerbations
- High mortality
- Difficulties with reimbursing criteria for antifungals since COPD is not considered to be a host factor
- Colonisation vs disease
IPA diagnosis in ICU patients

• EORTC/MSG Case Definitions \(^1\)
  
  – Difficult to apply outside high risk populations
  – Not useful to guide therapy

\(^1\) Ascioglu S. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants. *Clin Infect Dis* 2002
Proven and probable IPA without malignancy in ICU (’00-’03)

Meersseman et al. Invasive aspergillosis in critically ill patients without malignancy. AJRCCM 2004
COPD patients: benefits of ICU?

– 23 pts, 16 proven, 7 probable (repeated isolation)
  • recent steroid treatment, or intensification of steroid treatment
  • severe bronchospasm (12/23)
  • all required mechanical ventilation
  • diagnosis classified as
    – confirmed
      » positive lung tissue biopsy and/or autopsy
    – probable
      » repeated isolation of Aspergillus from the airways with consistent clinical and radiological findings
  
  – mortality 100%

Clinical characteristics of IPA in COPD

- Total number of patients: 56
- Age yrs (mean): 65.5
- Steroid treatment
  - At admission: 43
  - In hospital: 49
  - NA: 5
- Clinical signs
  - Antibiotic resistant pneumonia: 53
  - Dyspnoea exacerbation: 56
  - Wheezing increase: 52
  - Fever > 38°C: 31
  - Haemoptysis: 5
  - Tracheobronchitis (bronchoscopy): 6

Bulpa et al. IPA in patients with COPD. Eur Resp J 2007; 30: 782
Clinical characteristics

• Duration between symptoms and diagnosis days 12.5 days
• Ventilation
  • Invasive 43
  • Noninvasive 1
  • None 10
  • NA 2

• Outcome
  • Death 53 (95)
  • Survival 3 (5)

Bulpa et al. IPA in patients with COPD. *Eur Resp J* 2007; 30: 782
Why frequent in ICU? Why such a high mortality?

• Most severe exacerbations end up in ICU
• We love to give a lot of steroids
• We don’t think of aspergillosis
• Poor sensitivity of culture
• We don’t know what to do with a positive culture or direct examination
• Radiology doesn’t help us

Meersseman W, Lagrou K, Maertens J. Invasive aspergillosis in ICU. Clin Infect Dis ‘07
Significance of culture positivity

- IA diagnosed in 45/477 patients with “underlying pulmonary disease and positive culture”
- Positive predictive value lower than in haematology patients
- Colonisation vs true disease ???
  - Temporary passage ?
  - Long-term benign carriage ?

Medical Imaging and Timely Diagnosis of Invasive Pulmonary Aspergillosis

Koenraad H. Vandewoude¹ and Dirk Vogelaers²
¹Intensive Care Department and ²Department of Infectious Diseases, Ghent University Hospital, Ghent, Belgium

• Halo sign: only applicable to neutropenic patients
• Radiology in ICU “clouded” by atelectasis, pleural effusions, ARDS
• Necrotizing, cavitating lesions: not specific
Halo Sign (HS)

- CT analog of the discrete nodule
  1. Solid Macronodule (MN) ≥1 cm diameter
  2. Translucent ground glass halo

- Implications
  Early IPA
  Transient
  Better treatment response

- Other etiologies
CT of Lobular Consolidation

- Mild neutrophil dysfunction
- Neutrophilic exudate fills the airspace
- Consolidated 2° lobules
- Air bronchograms
- Many potential causes
Corticosteroids vs neutropenia: a different lung disease

As a consequence …

• Inflammatory reaction:
  - leads to encapsulation of the process
  - prevents at least partially invasion of hyphae in the blood (minor coagulation necrosis)
  - prevents leakage of antigens in blood
  - probably makes antigen markers in blood less suitable for diagnosis
Proven and probable IPA without malignancy in ICU (’00-’03)

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>n</th>
<th>Age, yrs (mean)</th>
<th>SAPS II (mean)</th>
<th>Predicted mortality, %</th>
<th>Observed mortality, %</th>
<th>Length of stay (days)</th>
<th>Culture positive,*</th>
<th>Asperg Ag** Positive*</th>
<th>Autopsy positive*</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>33</td>
<td></td>
<td>69</td>
<td>49</td>
<td>85</td>
<td>23</td>
<td>31/33</td>
<td>12/25</td>
<td>12/19</td>
</tr>
<tr>
<td>Systemic disease</td>
<td>14</td>
<td></td>
<td>60</td>
<td>50</td>
<td>93</td>
<td>18</td>
<td>10/14</td>
<td>7/11</td>
<td>6/9</td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>3</td>
<td></td>
<td>55</td>
<td>64</td>
<td>100</td>
<td>13</td>
<td>1/3</td>
<td>0/0</td>
<td>3/3</td>
</tr>
<tr>
<td>Solid organ transplants</td>
<td>9</td>
<td></td>
<td>51</td>
<td>47</td>
<td>100</td>
<td>22</td>
<td>6/9</td>
<td>4/9</td>
<td>3/6</td>
</tr>
<tr>
<td>Other</td>
<td>8</td>
<td></td>
<td>73</td>
<td>66</td>
<td>100</td>
<td>14</td>
<td>8/8</td>
<td>4/6</td>
<td>3/4</td>
</tr>
<tr>
<td>All</td>
<td>67</td>
<td></td>
<td>65</td>
<td>52</td>
<td>91</td>
<td>21</td>
<td>56/67</td>
<td>27/51</td>
<td>27/41</td>
</tr>
</tbody>
</table>

Meersseman et al. Invasive aspergillosis in critically ill patients without malignancy. AJRCCM 2004
Galactomannan in BAL

Diagnosis of IA in the ICU

Can we establish the diagnosis of IA earlier?

Prospective single center study in a medical ICU

Inclusion criteria: modified EORTC criteria ("classical" + COPD + cirrhosis + steroids)

BAL, serum GM, culture and CT scan according to clinical criteria

Hypothesis: galactomannan in BAL fluid leads to an early diagnosis of IA in the ICU; encapsulation of the infection in nonneutropenic patients prevents leakage in the blood
Inclusion criteria prospective study

“Modified” host factor (hemato, steroids, transplant cirrhosis, COPD)

+ 2/3 following features:

- Fever refractory to antibiotics (72 hrs)
- Clinical signs (new purulent secretions)
- New or deteriorating pulmonary infiltrates on chest X-ray
1109 admissions
Medical ICU
18 months
(06/05-12/06)
Modified EORTC criteria

n = 110

Solid organ transplants: n=6
Solid cancer: n=23
Cirrhosis: n=23
Other n=6
Hematological malignancy: n=36
Systemic disease: n=16
COPD: n=15

Proven: n = 26 .
## Performance GM in serum and BAL

<table>
<thead>
<tr>
<th>OD index cut-off:</th>
<th>1,5 BAL</th>
<th>serum</th>
<th>1,0 BAL</th>
<th>serum</th>
<th>0,7 BAL</th>
<th>serum</th>
<th>0,5 BAL</th>
<th>serum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity (%)</td>
<td>81</td>
<td>23</td>
<td>81</td>
<td>27</td>
<td>85</td>
<td>31</td>
<td><strong>88</strong></td>
<td>42</td>
</tr>
<tr>
<td>Specificity (%)</td>
<td>96</td>
<td>100</td>
<td>93</td>
<td>98</td>
<td>92</td>
<td>98</td>
<td>87</td>
<td>96</td>
</tr>
<tr>
<td>PPV (%)</td>
<td>81</td>
<td>100</td>
<td>79</td>
<td>88</td>
<td>73</td>
<td>89</td>
<td>72</td>
<td>85</td>
</tr>
<tr>
<td>NPV (%)</td>
<td>89</td>
<td>68</td>
<td>89</td>
<td>69</td>
<td>93</td>
<td>70</td>
<td>93</td>
<td>74</td>
</tr>
</tbody>
</table>

Meersseman et al. Galactomannan in BAL in ICU. AJRCCM ’07 (in press)
Performance GM in serum and BAL

Meersseman et al. Galactomannan in BAL in ICU. AJRCCM ’07 (in press)
Summary

• Three disease entities in COPD
  - aspergilloma
  - chronic aspergillosis
  - subacute invasive aspergillosis
• Controversial topic: no clear guidelines
• Studies warranted in
  - chronic aspergillosis: benefits of longterm triazole therapy
  - subacute IPA: pre-emptive approach based on galactomannan in BAL